【摘要】 目的 探讨沙利度胺对临床需单独或联合应用伊立替康化疗患者迟发性腹泻的防治作用。方法 收集84例应用伊立替康患者相关资料,其中治疗组(n=43)自化疗前一天起予以沙利度胺(口服100 mg,每晚睡前1次),持续1周;对照组(n=41)未应用沙利度胺。观察2组迟发性腹泻、严重腹泻和其他不良反应发生率,并进行统计学分析。结果 治疗组与对照组迟发性腹泻发生率分别为4.7%和34.1%,严重腹泻发生率分别为0和14.6%,2组相比差异有统计学意义(P<0.05);2组恶心、呕吐发生率比较差异有统计学意义(P <0.05),2组骨髓抑制、血栓形成、肝肾功能、便秘、皮疹、周围神经炎不良反应发生率比较差异无统计学意义(P>0.05)。结论临床应用沙利度胺可以降低伊立替康所致的迟发性腹泻、严重腹泻的发生率,用药安全,扩大了沙利度胺的临床适用范围。更多还原

【Abstract】 Objective To explore the preventive effects of thalidomide on delayed-onset diarrhea caused by irinotecan.Methods A total of 84 patients who took irinotecan were randomly assigned into a treatment group(n=43) and a control group(n=41).Patients in the treatment group received oral thalidomide 100 mg(once per day before sleep)for one week.Those in the control group did not take thalidomide.Then we observed the rates of delayed-onset diarrhea,severe diarrhea and other adverse reaction and performed statistical analysis.Results The rate of delayed-onset diarrhea was 4.7% in the treatment group and 34.1 % in the control(P> 0.05).The rate of severe diarrhea was 0 in the treatment group while 14.6% in the control(P <0.05).The treatment group presented the rates of nausea and vomiting significantly different from those in the control(P <0.05).No statistically significant difference was found between the two groups as to the function of the liver and kidney,the rates of myelosuppression,thrombosis,constipation,skin rashes and peripheral neuropathy(P>0.05).Conclusion Thalidomide treatment can reduce the rate of delayed-onset diarrhea caused by irinotecan,which is another indication of the medication.更多还原